jRCT2080221311未知3 期
Long-term study of HFT-290 in patients with chronic pain.
适应症
试验速览
- 阶段
- 3 期
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Multicenter, open-label, uncontrolled
入排标准
- 年龄范围
- No limit 至 No limit（—）
- 性别
- All
入选标准
- •Patients with chronic pain persisting for at least 12 weeks before obtaining informed consent
排除标准
- •Patients with abnormalities at the site of application
- •Patients in whom the primary cause of chronic pain (the target of evaluation) is considered to be persistent somatoform pain disorder
- •Patients who are scheduled to undergo an operation with a potential influence on the evaluation of pain for at least 7 days before starting administration of the investigational drug
结局指标
主要结局
-
efficacy, safety
次要结局
未报告次要终点
研究者
相似试验
未知
3 期
Phase III clinical study in patients with chronic painChronic painjRCT2080221563Hisamitsu Pharmaceutical Co., Inc.
进行中（未招募）
不适用
A phase III clinical study in patients with active rheumatoid arthritis who show an inadequate response or intolerance to previous or current treatmentRheumatoid ArthritisjRCT2011220026Zenyaku Kogyo, Co., Ltd.113
进行中（未招募）
1 期
A long-term follow-up study for patients treated with Galapagos CAR T cell therapiesRelapsed/refractory B-Cell non-Hodgkin lymphoma, Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Relapsed/refractory multiple myelomaMedDRA version: 21.0Level: LLTClassification code: 10051812Term: Small cell lymphocytic lymphoma Class: 10029104MedDRA version: 20.0Level: HLGTClassification code: 10025320Term: Lymphomas non-Hodgkin's B-cell Class: 10029104MedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104CTIS2023-510173-34-00Galapagos300
进行中（未招募）
不适用
A Long-term Continuation Study of Patients with Infantile-Onset Pompe Disease who were previously enrolled in Protocol AGLU01602Pompe disease is a rare metabolic muscle disease inherited in an autosomal recessive fashion. Pompe disease is caused by a deficiency of GAA, which is needed for the degradation of lysosomal glycogen. Pompe disease is characterized by organelle bound (lysosomal) accumulation of glycogen in many body tissues. In general, there is an inverse correlation between the amount of residual GAA activity in patients with Pompe disease and the severity of the disease.EUCTR2005-001629-27-DEGenzyme Europe BV17
进行中（未招募）
不适用
A Long-term Continuation Study of Patients With Infantile-Onset Pompe Disease WhoWere Previously Enrolled in Protocol AGLU01602Pompe disease or glycogenosis type IIMedDRA version: 6.1Level: HLTClassification code 10024579EUCTR2005-001629-27-ITGENZYME